These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36134681)

  • 1. Prognostic Factors for Clinical Outcomes in Patients with Newly Diagnosed Advanced-stage Hodgkin Lymphoma: A Nationwide Retrospective Study.
    Jerry Teng CL; Tan TD; Pan YY; Lin YW; Lien PW; Chou HC; Chen PH; Lin FJ
    Cancer Control; 2022; 29():10732748221124865. PubMed ID: 36134681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
    Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
    Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
    J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
    Jain H; Sengar M; Nair R; Menon H; Laskar S; Shet T; Gujral S; Sridhar E
    J Postgrad Med; 2015; 61(2):88-91. PubMed ID: 25766339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
    Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
    Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
    Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
    Ogura M; Itoh K; Kinoshita T; Fukuda H; Takenaka T; Ohtsu T; Kagami Y; Tobinai K; Okamoto M; Asaoku H; Sasaki T; Mikuni C; Hirano M; Chou T; Ohnishi K; Ohno H; Nasu K; Okabe K; Ikeda S; Nakamura S; Hotta T; Shimoyama M
    Int J Hematol; 2010 Dec; 92(5):713-24. PubMed ID: 21076995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
    Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry.
    Goveia L; Castro N; de Souza C; Colaço Villarim C; Traina F; Chiattone CS; Praxedes M; Solza C; Perobelli L; Baiocchi O; Gaiolla R; Boquimpani C; Buccheri V; Bonamin Sola C; de Oliveira Paula E Silva R; Ribas AC; Steffenello G; Pagnano K; Soares A; Souza Medina S; Silveira T; Zattar Cecyn K; Carvalho Palma L; de Oliveira Marques M; Spector N; Biasoli I
    Ann Hematol; 2023 Oct; 102(10):2815-2822. PubMed ID: 37474632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years.
    Andjelic BM; Mihaljevic BS; Jakovic LR
    Pathol Oncol Res; 2012 Jul; 18(3):675-80. PubMed ID: 22234624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
    Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
    Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K
    Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience.
    Potre O; Pescaru M; Sima A; Ionita I; Tudor R; Borsi E; Samfireag M; Potre C
    Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684063
    [No Abstract]   [Full Text] [Related]  

  • 19. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
    Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
    Evens AM; Hong F; Gordon LI; Fisher RI; Bartlett NL; Connors JM; Gascoyne RD; Wagner H; Gospodarowicz M; Cheson BD; Stiff PJ; Advani R; Miller TP; Hoppe RT; Kahl BS; Horning SJ
    Br J Haematol; 2013 Apr; 161(1):76-86. PubMed ID: 23356491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.